|Other Names||Chymase, Alpha-chymase, Mast cell protease I, CMA1, CYH, CYM|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7655b was selected from the C-term region of human CMA1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Major secreted protease of mast cells with suspected roles in vasoactive peptide generation, extracellular matrix degradation, and regulation of gland secretion.|
|Cellular Location||Secreted. Cytoplasmic granule. Note=Mast cell granules|
|Tissue Location||Mast cells in lung, heart, skin and placenta. Expressed in both normal skin and in urticaria pigmentosa lesions|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CMA1 is a chymotryptic serine proteinase that belongs to the peptidase family S1. It is expressed in mast cells and thought to function in the degradation of the extracellular matrix, the regulation of submucosal gland secretion, and the generation of vasoactive peptides. In the heart and blood vessels, this protein, rather than angiotensin converting enzyme, is largely responsible for converting angiotensin I to the vasoactive peptide angiotensin II. Angiotensin II has been implicated in blood pressure control and in the pathogenesis of hypertension, cardiac hypertrophy, and heart failure. Thus, this protein is a target for cardiovascular disease therapies.
Raymond,W.W., J. Immunol. 182 (9), 5770-5777 (2009)Chung,W.K., J. Heart Lung Transplant. 28 (4), 373-379 (2009)Hossny,E.M., J Investig Allergol Clin Immunol 18 (5), 376-381 (2008)
If you have any additional inquiries please email technical services at email@example.com.